草酸铂和伊立替康、氟尿嘧啶联合方案治疗晚期肠癌  

Treatment of advanced and metastatic colorectal cancer with combined chemotherapy based on oxaliplatin,irinotecan and fluorouracil

作　　者：惠锦林[1] 李红霞[1] 王彬[1] 梅蔚德[1] 

机构地区：[1]安徽省新华肿瘤医院肿瘤中心,安徽合肥230051

出　　处：《中国癌症杂志》2004年第4期345-347,共3页China Oncology

摘　　要：目的 :总结探讨草酸铂和伊立替康、氟尿嘧啶联合方案治疗晚期肠癌近期疗效及毒副反应。方法 :2 5例晚期肠癌 ,用草酸铂、伊立替康和氟尿嘧啶 +亚叶酸联合方案静脉应用或动脉介入 +静脉用药 ,治疗两周期评价疗效及相关症状改善 (DRSI)及毒副反应。结果 :经治疗动脉介入 +静脉用药组 15例 ,CR 1例 ,PR 9例 ,有效率 6 6 .6 %。静脉用药组 10例 ,PR 4例 ,有效率 4 0 .0 % ,两组疗效无显著差异 (P >0 .0 5 )。总有效率为 5 6 .0 %。 18例相关症状改善 ,毒副反应可耐受 ,未见严重不可逆反应。结论 :草酸铂和伊立替康和氟尿嘧啶联合方案治疗晚期肠癌复发或转移患者 ,疗效明确 ,安全有效 ,毒副作用小 ,无叠加毒性 ,可明显改善患者症状 ,提高生存质量。Purpose:To investigate the efficacy of combined chemotherapy based on Oxaliplatin(OXA),Irinotecan(CPT-11)and fluorouracil(5-Fu),for treatment of relapse and metastatic colorectal cancer and its side-effects. Methods:25 cases of relapse and metastatic colorectal cancer by interventional arterial chemotherapy and iv drip,based on Oxaliplatin,Irinotecan and 5-Fu,CF,then after 2 cycles of treatment,the efficacy and clinical symptoms were evaluated. Results:After treatment,the terventional arterial group 1/15 achieved CR,9/15 achieved PR,the response rate was 66.7%. In the iv drip group 4/10 achieved PR,response rate was 40.0%,there was no significant difference between the two groups(P>0.05),the overall response rate was 56.0% .Symptoms(18/25) related to cancer improved and side-reactions were tolerable. Conclusions:Treatment of relapse and metastatic colorectal cancer with combined chemotherapy based on oxaliplatin,irinotecan and 5-Fu by arterial intervention and iv drip is safe and effective,with only slight side-effects. This treatment can improve the symptoms and life quality of patients.

关 键 词：复发转移性肠癌 草酸铂 伊立替康 化疗 

分 类 号：R735.3[医药卫生—肿瘤]